Forbius Announces the First Patient Dosed in a Phase 1b Diffuse Cutaneous Systemic Sclerosis Trial of AVID200, a Novel TGF-beta 1 & 3 Inhibitor

Forbius, a clinical-stage company that develops biologics for the treatment of fibrosis and cancer, announced today that the first patient has been dosed in a diffuse cutaneous systemic sclerosis (SSc) Phase 1b trial with AVID200, a rationally designed and highly potent inhibitor of TGF-beta 1 & 3.